CONTINUUS awarded SBIR Phase II grant from the NSF
- CONTINUUS Pharma
- Mar 1, 2016
- 1 min read
Updated: Aug 12, 2024
Tuesday, March 1st, 2016 - General News
CONTINUUS Pharmaceuticals was awarded a Phase II SBIR grant from the National Science Foundation to further develop its breakthrough ICM technology. This Phase II grant consists of $750,000 over a two year period, with the opportunity for additional matching funds to facilitate commercial partnerships.
Comments